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Abstract
Background: Independent veriﬁcation of the dose delivered by complex radiother-
apy can be performed by electronic portal imaging device (EPID) dosimetry. This
paper presents 5‐yr EPID in vivo dosimetry (IVD) data obtained using the Dosimetry
Check (DC) software on a large cohort including breast, lung, prostate, and head
and neck (H&N) cancer patients.
Material and Methods: The difference between in vivo dose measurements
obtained by DC and point doses calculated by the Eclipse treatment planning sys-
tem was obtained on 3795 radiotherapy patients treated with volumetric modulated
arc therapy (VMAT) (n = 842) and three‐dimensional conformal radiotherapy
(3DCRT) (n = 2953) at 6, 10, and 15 MV. In cases where the dose difference
exceeded ±10% further inspection and additional phantom measurements were per-
formed.
Results: The mean and standard deviation ðl rÞ of the percentage difference in
dose obtained by DC and calculated by Eclipse in VMAT was: 0:19  3:89% in
brain, 1:54  4:87% in H&N, and 1:23  4:61% in prostate cancer. In 3DCRT, this
was 1:79  3:51% in brain, 2:95  5:67% in breast, 1:43  4:38% in bladder,
1:66  4:77% in H&N, 2.60 ± 5.35% in lung and 3:62  4:00% in prostate can-
cer. A total of 153 plans exceeded the ±10% alert criteria, which included: 88 breast
plans accounting for 7.9% of all breast treatments; 28 H&N plans accounting for
4.4% of all H&N treatments; and 12 prostate plans accounting for 3.5% of all pros-
tate treatments. All deviations were found to be as a result of patient‐related
anatomical deviations and not from procedural errors.
Conclusions: This preliminary data shows that EPID‐based IVD with DC may not
only be useful in detecting errors but has the potential to be used to establish site‐
speciﬁc dose action levels. The approach is straightforward and has been imple-
mented as a radiographer‐led service with no disruption to the patient and no
impact on treatment time.
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1 | INTRODUCTION
It is recommended that all radiotherapy centers in the United King-
dom have a protocol for accurately measuring the dose delivered to a
patient during a course of radiotherapy and comparing this to the
planned dose.1–4 This approach, commonly known as transit or IVD,
has its origins in the 1980s and 1990s when radiographic and radio-
chromic ﬁlms were used for this purpose. More recently thermolumi-
nescent detectors (TLDs), semiconductor diodes, metal‐oxide ﬁeld
effect transistors (MOSFETs), and optically stimulated luminescence
dosimeters (OSLDs) have been used for point dose measurements.5–7
However, there are inherent difﬁculties with each of these
approaches, which have been comprehensively reviewed in several
key publications.8–11 Many of the limitations of these dosimeters can
be overcome by the use of EPIDs, which although developed primar-
ily for imaging, are now widely used as dosimeters and consequently
for treatment veriﬁcation.11–15 EPIDs, like the aforementioned
dosimeters, can be used for either pretreatment veriﬁcation without
the patient present or, as discussed here, for IVD where the patient
is present. The main challenge in using EPIDs as dosimeters is in the
mapping between the EPID images into dose, with two techniques
commonly used for this purpose. In the ﬁrst a portal dose image is
predicted from the treatment plan and the computerized tomography
(CT) images used for planning, which is compared to the measured
portal dose image. In the second, the measured portal dose image is
combined with a back‐projection algorithm to calculate the dose in
any given CT voxel and hence received by a patient.
The most widespread use of EPIDs as dosimeters has been in
pretreatment veriﬁcation.16–18 However, there are limitations associ-
ated with pretreatment veriﬁcation for detecting certain errors such
as those associated with patient anatomy.19 Furthermore patient‐
speciﬁc pretreatment veriﬁcation requires additional quality assur-
ance (QA) procedures and linear accelerator time. Using EPID‐based
IVD for patient‐speciﬁc QA overcomes these weaknesses and allows
veriﬁcation of the radiotherapy workﬂow using an independent tech-
nique. This was demonstrated in practice in a large‐scale study of
4337 patients veriﬁed using in vivo dosimetry between 2005 and
2009 at the Netherlands Cancer Institute. Of the 17 serious errors
detected nine would not have been detected by standard pretreat-
ment veriﬁcation.19 This was endorsed further in a recent large‐scale
review by Mijnheer et al. 20 reporting on 3‐yr experience of 3D EPID
IVD. Clinically relevant deviations were detected in approximately 1
in 430 patient treatments. These changes would not have been
detected by pretreatment veriﬁcation as they were as a result of
deviations from routine clinical procedure and anatomical changes.
There is also compelling evidence for treatment adaptation using
dosimetric information acquired by this approach. In a recent study
of ﬁve patients 3D EPID dose was combined with cone‐beam CT
(CBCT) imaging to detect atelectasis‐induced dose changes in lung
cancer patients where plan adaptation would be beneﬁcial.21
There are now commercial systems available for IVD including:
Epiqa by EPIdos, Bratislava, Slovakia;22 EPIGray by DOSIsoft;14
Dosimetry Check (DC) by Math Resolutions LLC, Columbia, MD,
USA23–26 and some institutions have developed in‐house solutions
for IVD.27,28 Clinical experience from these systems is accumulating
with a recent study from the United Kingdom on 58 patients clearly
demonstrating the advantage of the commercial in vivo dosimetry
system EPIgray for detecting anatomical changes in three of the 20
prostate cancer patients in the cohort. All EPID images used in the
study were acquired on Elekta Synergy and Precise linear accelera-
tors (Elekta, Stockholm, Sweden) equipped with iView a‐Si portal
imagers (Perkin Elmer, Beaconsﬁeld, UK).29 Here, we present com-
plementary data obtained from our 5‐yr experience of using the DC
EPID IVD QA software on Varian C‐Series and Truebeam linear
accelerators (Varian Medical Systems, Inc., Palo Alto, CA, USA)
equipped with Varian a‐Si 1000 EPIDs on a range of tumor sites
including: breast; prostate; H&N; lung and brain cancer.
2 | MATERIAL AND METHODS
2.A | Dosimetry Check — technical overview
This section presents a technical overview of the DC software
including general commissioning and the steps involved in conﬁgur-
ing it for use with a Varian aSi 1000 EPID device ﬁtted to a Varian
C‐series linear accelerator. This information is also valid for other
EPID/linear accelerator conﬁgurations.
The DC software has two main technical elements. The ﬁrst is
that there is a mapping between the EPID ﬂuence and the monitor
units (MU) that would produce the same exposure at the center of a
10 × 10 cm2 ﬁeld at the appropriate reference conditions. The out-
put of this mapping is termed the relative monitor unit (RMU). The
second is that the scatter within the EPID housing must be taken
into account to allow this new unit of RMU to independently calcu-
late the dose received by a patient. This is done by deconvolution of
the EPID ﬂuence with the point spread function (PSF) of the EPID,
which produces the RMU in terms of in‐air ﬂuence.
In practice the PSF has to take into account the dependence of
the EPID on the input beam energy and the additional low‐energy
scatter radiation reaching the EPID from the presence of a patient in
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the beam. In DC this is done at commissioning by calculating the
PSF for a beam incident on and exiting water at regular intervals
from 5 cm up to a maximum of 60 cm between the EPID and the
radiation source.
2.A.1 | Relative monitor units
To obtain the absorbed dose (cGy) from the EPID, integrated EPID
images are ﬁrst mapped to RMU, which was deﬁned by Renner as
the number of MU that produces the same EPID pixel gray levels as
a well‐controlled calibration condition.24 This is usually the
10 × 10 cm2 reference ﬁeld that is used to deﬁne the output of a
linear accelerator, typically as, “1.0 cGy/MU at 10 × 10 cm2 ﬁeld size
at 100 cm from the surface of water at 1.5 cm depth for 6 MV
x raysa.” In the case of open square ﬁelds this may be thought of as
the collimator scatter factor (SC) multiplied by the output (MU).
The ﬁrst step in converting an integrated EPID image into RMU
is to establish the relationship between the EPID signal at the cen-
tral axis of a 10 × 10 cm2 ﬁeld and the corresponding MU required
to obtain this signal. To account for points not on the central axis,
or off‐axis points, the in‐air off‐axis ratio (OAR) along the diagonals
of a 40 × 40 cm2 ﬁeld are measured to obtain the average OAR.
Multiplying EPID pixels at a distance r cm from the central axis by
this value restores the horns on a crossbeam proﬁle, which arise as a
result of using a ﬂattening ﬁlter.
2.A.2 | In vivo dose evaluation
From this knowledge of the ﬂuence at each pixel of the EPID, which is
in RMU, and the beam geometry and patient CT it is possible to ray
trace from the x‐ray source through the equivalent thickness of water
that would produce this ﬂuence. The same principle is applied when
the planning CT is used in place of water and ray tracing is used to
establish the dose at a point in the CT and hence the patient. The ﬂu-
ence map collected by the EPID image is the source of input for the
DC dose calculation engine. This ﬂuence map is used to parameterize
the independent pencil beam dose calculation (PBC) algorithm that is
used by DC. The dose calculated by DC is next compared to the dose
matrix calculated by the treatment planning system. Quantitative eval-
uation of the difference between the planned and measured dose dis-
tribution is carried out in DC using either whole volume or partial
volume gamma analysis or by a point dose comparison.30
The DC software platform has been used for IVD at the Edin-
burgh Cancer Centre since 2011 to monitor 3795 patients treated
with VMAT and 3DCRT at beam energies 6, 10, and 15 MV. This
included the cancer sites abdominal (n = 38); brain (n = 256); breast
(n = 1215); genitourinary (n = 246); pelvic (n = 318); H&N (n = 636);
lung (n = 664); prostate (n = 345); other (n = 77).
2.B | Dosimetry Check — clinical implementation
To conﬁgure the DC software for routine clinical use and to mea-
sure the dose received by a patient, EPID Sc measurements must
be obtained at different beam energies at all available ﬁeld sizes
and at different water equivalent depths. Integrated EPID images
of water were acquired on 10 ﬁeld sizes ranging from 2 × 2 to
28 × 20 cm2 and 10 water depths in the range from 5 to 60 cm
at a focus to imager distance (FID) of 150 cm and 100 MU. This
procedure was repeated on the three C‐series and two Truebeam
linear accelerators used at Edinburgh Cancer Centre. The FID was
held constant and the treatment isocenter was always at the cen-
ter of the water phantom. A ﬁtting program, which is a standard
module within DC, was used to ﬁt the measured collimator scatter
(SMEASC Þ to the calculated collimator scatter ðS
CALC
C Þ using a downhill
search optimization algorithm.25 Convergence was obtained when
the variance, deﬁned by,
r2 ¼
Xm
i
SMEASC  S
CALC
C
m
 2
(1)
over m data points was within 2%. Figure 1 shows the percentage
difference between SMEASC and S
CALC
C for 6 and 10 MV photon
energies at a range of different ﬁeld sizes. Following successful
ﬁtting of the data, it is possible to use DC to reconstruct the
dose to a patient based on acquisition of an EPID integrated
image.
Because DC is a completely independent veriﬁcation system
the treatment plan and associated CT images must be exported
from the treatment planning software and manually imported into
the DC software where reports are produced. Here, these were
used to conﬁrm the safe delivery of a treatment based on the
Ionising Radiation (Medical Exposure) Regulations 2000 (IRMER)31
with alerts triggered when the dose difference between DC and
Eclipse exceeded ±10% at the plan reference point. In the event
that the dose exceeded this level, a full 3D gamma analysis was
performed on the treatment plan with DDM ¼ 4% and
DdM ¼ 4mm. This led to further positional and patient‐speciﬁc QA
checks being performed.
3 | RESULTS
3.A | Conversion to RMU and data ﬁtting
The EPID images acquired over the range of depths and ﬁeld sizes
previously deﬁned were converted into RMU using an in‐built con-
version function within DC. This function takes all of the DICOM
images acquired at a particular depth as input and, together with an
open ﬁeld in‐air calibration image, performs the RMU conversion
previously described.
Fitting of the measured dose to water and the calculated dose
to water by DC requires an initial estimate, which was ﬁrst per-
formed using the approach recommended by Math Resolutions. The
percentage difference between SMEASC and S
CALC
C at all depths was in
general found to be within ±2.5% for all ﬁeld sizes between
2 × 2 cm2 and 28 × 20 cm2. Figure 1 shows Sc on all ﬁelds and
depths obtained on a Varian Truebeam linear accelerator with an
aSI 1000 EPID on an Exact‐Arm at 6 and 10MV photon energies.
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F I G . 1 . Percentage difference between
SMEASC to S
CALC
C on ﬁeld sizes from 2 × 2
cm2 to 28 × 20cm2 at 10 water depths in
the range 5 cm to 60 cm at a focus to
imager distance (FID) of 150 cm at: (a) 6
and (b) 10 MV photon energies.
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Figure 2 shows the measured and computed dose proﬁles recon-
structed from the EPID ﬂuence along the central axis when a 6 and
10 MV photon beam was delivered to a 10 × 10 cm2 ﬁeld at a
range of depths. The computed dose proﬁle was obtained using the
Eclipse treatment planning system (Varian Medical Systems, Inc.,
Palo Alto, CA, USA).
F I G . 2 . Proﬁles of measured dose and
computed dose along the central axis of a
10 × 10 cm2 ﬁeld irradiated by 6MV
photons at depths of 1.5 cm, 5.0 cm, 10.0
cm, 15.0 cm, 20.0 cm, and 25 cm at (a) 6
and (b) 10 MV photon energies.
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F I G . 3 . Transit dosimetry point dose
measurements on: (a) prostate; and (b)
H&N cancer patients treated between
2011 and 2016.
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F I G . 4 . Transit dosimetry point dose
measurements on: (a) breast; and (b) lung
cancer patients treated between 2011 and
2016.
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3.B | Radiotherapy courses and patients
Figures 3 and 4 show the percentage difference in point doses cal-
culated by Eclipse and measured by DC for all prostate, H&N, breast
and lung cancer patients treated between 2011 and 2016. Table 1
shows the range of treatment sites, the total number of treatment
plans veriﬁed and the alerts produced by the system. The mean and
standard deviation ðl rÞ of VMAT cases was found to be
TA B L E 1 Details of the range of treatment sites, total number of treatment plans veriﬁed and the alerts produced above the 10% threshold
from 2011 to 2016.
Treatment group/site No. of Plans
Planning technique Mean differencea μ ± σ
No. of alerts
VMAT 3DCRT VMAT 3DCRT >10%
Abdominal cancer 38
Abdomen 30 4 26 – 1.75 ± 5.25 1
Pancreas 3 – 3 – – 0
Spleen 2 – 2 – – 0
Stomach 3 – 3 – – 0
Brain cancer 256
Brain 241 87 154 −0.19 ± 3.89 1.79 ± 3.51 2
Brainstem 5 2 3 – – 0
Cavern sinus 1 1 – – – 0
Chordoma 1 1 – – – 0
Clivus 1 1 – – – 0
Meningioma 3 2 1 – – 0
Pituitary 4 4 – – – 1
Breast cancer 1215
Breast 1117 – 1117 – −2.95 ± 5.67 88
Chest wall 91 – 91 – 0.30 ± 6.22 6
Lymphatics 7 – 7 – – 1
Genitourinary cancer 246
Anus 27 5 22 – −4.99 ± 2.46 0
Esophagus 61 2 59 – 1.03 ± 4.97 3
Rectum 158 – 158 – −2.77 ± 4.12 0
Pelvic cancer 318
Bladder 104 4 100 – −1.43 ± 4.38 2
Cervix 42 – 42 – −4.49 ± 4.61 3
Endometrium 68 – 68 – −5.58 ± 3.19 1
Gynecological 53 – 53 – −3.74 ± 4.47 0
Pelvis 47 – 47 – −3.76 ± 4.55 1
Uterus 1 – 1 – – 0
Vagina 2 – 2 – – 0
Vulva 1 – 1 – – 0
Head and neck cancer 636
Head and Neck 636 435 201 1.50 ± 4.87 1.66 ± 4.77 28
Lung cancer 664
Lung 663 1 662 – 2.61 ± 5.35 2
Alveleolus 1 1 – – – 0
Prostate cancer 345
Prostate 345 285 60 1.23 ± 4.61 −3.62 ± 4.00 12
Other cancers 77
Miscellaneous 77 7 70 2
Total 3795 842 2953 – – 153
aMean and standard deviation are provided only where there are sufﬁcient statistical data.
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0.19 ± 3.89% in brain, 1.50 ± 4.87% in H&N, and 1.23 ± 4.61% in
prostate cancer patients (Table 1). The mean and standard deviation
of 3DCRT cases was found to be greater for each of these treat-
ments, 1.79 ± 3.51% in brain, 1.66 ± 4.77% in H&N, and
3:62 4:00% in prostate cancer patients (Table 1). The total num-
ber of alerts produced at the ±10% action level used in routine clini-
cal practice was 153 with the majority of the alerts found in breast
cancer patients, n = 88, which represented 7.8% of all breast cancer
patients monitored between 2011 and 2016. In the H&N cancer
patient cohorts, there were 28 alerts representing 4.4% of the
patients monitored and in prostate there were 12 alerts representing
3.5% of the patients monitored. In all of these cases further investi-
gation using 3D gamma analysis and additional patient‐speciﬁc QA
found no IRMER reportable treatment errors.
4 | DISCUSSION
With the signiﬁcant advances in radiotherapy delivery techniques such
as IMRT and VMAT and their widespread adoption there is a pressing
need for improved QA procedures that check the validity of these
techniques in a clinically acceptable timeframe. Moreover it is now
recommended, “for most patientsb”, that there is an independent IVD
veriﬁcation of the dose delivered from complex radiotherapy treat-
ments at the beginning of treatment.1 Many departments have investi-
gated the use of different detectors such as TLDs, semiconductor
diodes, and MOSFETS for IVD, however, the efﬁcacy of these detec-
tors is signiﬁcantly affected by positioning, dose gradient and the
increased QA time required to acquire and process the readings. The
results presented here demonstrate that EPID‐based IVD using DC is a
practical method for monitoring patients during treatment.
What is interesting to note from the 3DCRT IVD results is the
diversity in the percentage dose difference between DC and Eclipse
in breast, lung, H&N, and prostate cancer patients. In breast there
was a ‐2.95% mean difference between the dose calculated in
Eclipse and the IVD dose at a deﬁned reference point. In lung there
was a 2.6% difference, in H&N a 1.66% difference and in prostate a
−3.62% difference. While these results indicate that the IVD values
obtained by measurement are, in general, within the departmental
tolerance of ±10% for all treatment sites they highlight systematic
differences in the point dose measurements used for veriﬁcation of
breast, lung, H&N, and prostate cancer treatments. This may be as a
result of the different approaches used for planning these treatments
and selection of the reference point. It may also be due to the fun-
damental technical differences between DC and Eclipse, which
requires further investigation.
Ninety‐six percent of the 3795 patients included passed the
departmental alert criteria set for an acceptable difference (±10%)
between the planned and delivered (in vivo) dose. Of those cases
that exceeded the ±10% tolerance the majority were found to be in
patients with breast, prostate, and H&N cancer. The reason for the
alerts in the breast group was due to several compounding factors.
These were (a) changes in the volume of breast irradiated at each
fraction due to the inherent difﬁculties in positioning of the breast;
(b) chest wall irradiation, particularly the impact of rib structures in
the ﬁeld and the resulting uncertainties in the dose; (c) in nodal
breast irradiation where the EPID imager position has to be shifted,
no off‐axis correction is currently applied in the calculation; (d) cur-
rently breast patients are treated in free‐breathing mode, adopting a
breath‐hold technique will improve positioning and reduce dosimetric
uncertainty.
In the prostate cohort the failures were due to bladder and rectal
ﬁlling and in the H&N cancer group the alerts were as a result of
weight loss and choice of the reference point used for analysis.
In the future the availability of IVD data, such as the data pre-
sented here, could be a powerful indicator of suboptimal treatments
if correlated with long‐term patient follow‐up or outcome data. It
could also be used, if processed immediately, to identify the correct-
ness of individual multileaf collimator (MLC) ﬁelds 32 and to identify
signiﬁcant anatomical changes such as those seen in H&N cancer
patients experiencing weight loss during treatment.33
After the DC software obtains the in‐air ﬂuence in RMU it is possi-
ble to independently calculate the dose delivered to a given patient
using the original planning CT scan. Currently the DC software uses a
PBC algorithm to calculate this dose while the Eclipse treatment plan-
ning system used the Analytical Anisotropic Algorithm (AAA).34 The
AAA algorithm has been shown to result in a lower mean dose than
the PBC and in general a reduction in dose to the planning target vol-
ume (PTV), which may in part account for the differences between the
calculated and measured doses.35 Other factors that contribute to the
difference in dose observed in Fig. 2 include the EPID detector off‐
axis energy response and the ﬁtting parameters for all ﬁeld sizes and
depths acquired by DC. To account for a portion of these differences a
collapsed cone algorithm is currently under development by Math Res-
olutions, which will improve the accuracy of the dose calculation in
DC and ultimately reduce the variability in the results.36
The percentage difference between the measured and calculated
Sc was found to be within ±1.0% for ﬁeld sizes between 5 × 5 cm2
and 20 × 20 cm2. The largest difference was found at the smallest
(2 × 2 cm2 and 3 × 3 m2) and largest (28 × 20 cm2) ﬁeld sizes inves-
tigated. With the substantial increase in the use of small radiother-
apy ﬁelds, particularly for hypofractionation techniques where high
doses per fraction are delivered, it is important to obtain a better
match of Sc.37
The role of checking has been identiﬁed as a key element when
independently verifying the integrity of a treatment plan.38 The Edin-
burgh Cancer Centre has implemented a radiographer‐led IVD ser-
vice for the vast majority of patients treated with radical intent. This
has not only improved the efﬁciency and widespread deployment of
this service but more importantly by involving radiographers at this
stage of the radiotherapy chain a further check, independent of the
existing MU check, has been introduced.
Presently the DC software is used for all radical treatments at
the Edinburgh Cancer Centre where the ﬁeld dimensions do not
exceed the EPID imager dimensions. Since full clinical implementa-
tion DC‐based IVD has not identiﬁed any reportable incidents and
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has proven to be invaluable at identifying and correcting for anatom-
ical changes such as in the case where the difference between DC
IVD and Eclipse was −10.65% at the reference point of a bladder
cancer patient. A decision was taken to repeat DC IVD at the sec-
ond fraction where the difference was −11.80%, which prompted a
closer inspection of the treatment plan. This revealed that there was
an excessive amount of bowel gas at the time of the treatment plan-
ning CT, which was not present at the time of treatment. The
patient was rescanned, replanned, treated, and DC IVD used to con-
ﬁrm that the changes made were indeed appropriate. Figure 5 shows
the 1D proﬁle through the bladder in the anterior posterior (AP)
direction in which it is clear that there is a much better match
between the measured and planned dose after the rescan. The use
of DC IVD for this case proved particularly helpful.
5 | CONCLUSIONS
The ability to perform patient‐speciﬁc QA is now an accepted
requirement in modern radiotherapy. This paper presents preliminary
data, with a focus on safety, showing that EPID‐based IVD with DC
has signiﬁcant potential for this. From knowledge of the expected
difference between the in vivo dose and the planned dose, collected
on a large number of cases, it may be possible to set site‐speciﬁc
alert criteria for a given treatment site. Furthermore, this approach
has the potential to identify suboptimal treatments much earlier than
is currently possible.
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NOTES
a This is the deﬁnition of machine output at the Edinburgh Cancer Centre.
b This phrase was extracted verbatim from Ref. [1]
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